Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apalutamide added to radiotherapy and LHRH agonist for high-risk recurrent hormone-sensitive prostate cancer
2019-002957-46Phase 3Active
- Sponsor
- Janssen Pharmaceutical
- Start
- Mar 2020
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of apalutamide in prostate cancer (PCa) and recurrent prostate cancer (RPC) (3 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: PSMA-PET metastatic progression-free survival. Started Mar 2020; status: active.
02
Drugs
apalutamide
03
Conditions
prostate cancer (PCa)recurrent prostate cancer (RPC)
Beyond the preview
Go deeper on 2019-002957-46.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-002957-46.